Dr. Reddy's Laboratories stock
RDYNYSEDr. Reddy's Laboratories Limited, HealthcareISIN US2561352038
62Score 62 out of 100, Neutral
Price and trend
65 / 100
Price history
+6.4% in one yearThe chart shows daily closes over 20 years, adjusted for stock splits and without dividends. Click into the chart to set a price alert at that price.
Above the 200-day line: the price is 11% above it.
Since November 2025 the 50-day line has been below the 200-day line; the trend has turned down.
Overheated: the price has risen very quickly lately (RSI 77).
The price is 4.2% below its 52-week high. Largest decline in 20 years: 60% (January 2007 to March 2009).
Chart figures for advanced users
- SMA 50$12.99
- Average price of the last 50 trading days, shows the short-term trend.
- SMA 200$13.27
- Average price of the last 200 trading days, shows the long-term trend.
- RSI (14)77
- Relative strength over the last 14 days on a scale from 0 to 100. Above 70 the price counts as overheated, below 30 as sharply fallen.
- MACDabove the signal line
- Compares a fast and a slow price average. Above its signal line momentum is rising, below it momentum is fading.
- Support$11.38
- The lowest closing price of the last twelve months.
- Resistance$15.38
- The highest closing price of the last twelve months.
Snapshot
Computed from the data by fixed rules, no AI
- Dr. Reddy's Laboratories Limited belongs to the Drug Manufacturers (Specialty & Generic) industry (India) and, with a market value of $12.28B, is number 22 of 77 companies in its industry on MEQIRI.
- This is an American depositary receipt (ADR).
- In fiscal 2026 it reported revenue of $3.76B (up 8.6% year on year) and earnings of $479.22M (down 20.3%).
Show more
- MEQIRI Score 62 out of 100 (Neutral): rank 244 of 702 in Healthcare, median 53.
- The P/E is 41.2 (Drug Manufacturers (Specialty & Generic) median 18.9, own median of recent years 16.9).
- Our model puts fair value at $9.68, with the price 52% above it.
In plain words
The numbers on this page in plain words, written by an AI
Strengths
- Growing faster than its industryRevenue up 168% a year since 2021, Drug Manufacturers (Specialty & Generic) median 8.7%.Growth 63
- Analysts expect strong earnings growthUp 29.3% a year through 2028 (estimates from 3 analysts).Growth 63
- Earnings per share growingUp 21% a year since 2021.Growth 63
Weaknesses
- Richly valuedP/E 41.2, Drug Manufacturers (Specialty & Generic) median 18.9, own median 16.9.Valuation 35
- Above fair valuePrice 52% above the fair value of $9.68.Valuation 35
- Margin fallingOperating margin 13.8%, average of the prior years 22.1% (to 2025).Profitability 52
Its standout strengths are stability and momentum, while valuation holds the score back.
Daily figure as of 13 Nov 2026
How the score is calculatedScore overview
The fundamentals are in the middle range.
Score history
The full history of up to 20 years comes with MEQIRI Pro.
See plansCrash risk medium
How well MEQIRI warnsIn the middle among smaller stocks.
From 2016 to 2025, 20 in 100 such stocks fell 30% or more within a year, against a group average of 23 in 100.
What lowers it
- price near its 52-week high
Valuation
Valuation signal
Significantly overvaluedIn our model the price counts as cheap below $7.44 and expensive above $13.82 (uncertainty medium, based on the price swings of the past year).
The two parts of the fair value come to $12.59 (cash-flow model) and $6.76 (industry comparison), and the gap between them shows how uncertain the estimate is. The price is above both.
Calculated with a cost of equity of 12.6%. At 13.6% the fair value would be $8.64, at 11.6% it would be $11.16.
Valuation metrics
Half from the cash-flow model, half from earnings times the industry P/E (18.9).
Calculate with your own assumptionsCompany performance
This shows several years of history with an automatic assessment.
Revenue
In the twelve months to 30 Sep 2026, revenue fell 3.1% on the twelve months before. Revenue has grown solidly since 2007, at about 9% per year.
Margins
- Gross margin
- Operating margin
- Net margin
In fiscal 2026: gross 53%, operating 14%, net 13%.
Debt & balance sheet
latest quarterThe balance sheet is solid, with low debt and comfortable interest coverage.
Earnings
- Next earnings
- 22 Jan 2027in 70 days
- Last reported
- 23 Oct 2026above expectations
Analyst estimates
Analysts have raised their 2028 earnings estimate by 4.8% since 15 Oct 2026.
- Earnings per share
- 43.9+3.2%
- Revenue
- $3.78B+1.3%
- Earnings per share
- 59.1+4.8%
- Revenue
- $4.24B+1.8%
MEQIRI has stored the estimates since 15 Oct 2026. Until 30 days are available, the card shows the change since that day. Mean estimate according to Financial Modeling Prep. No price target and no recommendation.
Company outlook confirmed
Share price after the results: −6.1%The company remains confident of a strong second half and still expects an EBITDA margin around 20% without semaglutide, with a tax rate of 24% to 25%.
“Narasimham: Our tax rate is around 24%-25% on the full year basis.”The outlook is not part of the score and not a recommendation to buy or sell.
From the earnings call on 22 Jul 2026 (fiscal Q1 2027), read by AI.
Insiders
Open-market purchases and sales by executives, board members and major holders
No open-market purchases or sales in the last 6 months.
Source: Form 4 filings with the US Securities and Exchange Commission. Grants, option exercises, gifts and tax withholdings are hidden. Not a recommendation to buy.
What happened at Dr. Reddy's Laboratories
The key events of the last six months from our own data. A click takes you to the matching card.
Sector comparison
702 rated companies in Healthcare
- This company
- 62
- Sector median
- 53
Categories against the sector median
The median is the middle value: half of the companies in the sector lie above it, half below. Categories with too few comparable companies are left out.
Competitors in Drug Manufacturers (Specialty & Generic)
The next larger and next smaller companies by market value
- Yunnan Baiyao Group000538.SZ $14.63B67
- Laurus LabsLAURUSLABS.NS $13.78B70
- Elanco Animal HealthELAN $13.25B48
- Zydus LifesciencesZYDUSLIFE.NS $12.79B69
- CiplaCIPLA.NS $12.09B67
- Zhejiang NHU002001.SZ $11.75B75
- Mankind PharmaMANKIND.NS $11.58B65
- Aurobindo PharmaAUROPHARMA.NS $11.05B67
ETFs that hold Dr. Reddy's Laboratories
Held by 26 ETFs on Xetra. Shown per index: the ETF with the largest weight.
| ETF | Weight | Cost | Fund size |
|---|---|---|---|
| iShares MSCI India UCITS ETFQDV5 | 0.51% | 0.65% | €4.98B |
| iShares Edge MSCI EM Value Factor UCITS ETF5MVL | 0.49% | 0.40% | €1.51B |
| iShares Edge MSCI EM Minimum Volatility UCITS ETFEUNZ | 0.43% | 0.40% | €435.04M |
Show 5 more
| iShares MSCI EM CTB Enhanced ESG UCITS ETFEDM2 | 0.19% | 0.18% | €7.25B |
| Amundi MSCI EM Asia ESG Broad Transition UCITS ETF AccLCUA | 0.18% | 0.25% | €661.06M |
| Amundi MSCI Emerging Markets ESG Selection UCITS ETF DR (C)SADM | 0.12% | 0.18% | €1.07B |
| Invesco FTSE All-World UCITS ETF USDFTWD | 0.11% | 0.15% | €4.88B |
| iShares MSCI EM Asia UCITS ETFCEBL | 0.08% | 0.20% | €7.14B |
Holdings as reported by the funds via FMP, excluding swap ETFs (their holdings are only collateral).
Data status and sources
- Score
- Daily value of 13 Nov 2026, recalculated nightly
- Price
- Closing price of 12 Nov 2026
- Latest annual report
- Fiscal year 2026, period end 31 Mar 2026
- Currency
- Amounts in US dollars, converted at the ECB reference rate of 12 Nov 2026 ($1 = ₹94.0836)
- Source
- Financial statements, ratios and prices from Financial Modeling Prep (FMP), based on the company's reports. MEQIRI calculates the score and fair value from them.
Mandatory disclosures for this rating
- ; time horizon around 12 months
- Rated Neutral, published since 7 Nov 2026 (in the score history since 10 Jul 2026)
- Valuation signal Overvalued since 7 Nov 2026
- End-of-day prices, metrics cached for up to 24 hours
- Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
- Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
- Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.